MIRM · Mirum Pharmaceuticals Inc
United States · RS rating 18 · As of 2026-10-14
| Price | 79.96 USD |
|---|---|
| 1-day change | +0.4% |
| RS rating (overall / 1M / 3M / 12M) | 18 / 16 / 11 / 61 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 32 / 22 / 18 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -12063.5% |
| Sales growth Q/Q | +12.0% |
| Distance from 52-week high | +37.8% |
| Market cap (USD) | $5.5B |